Podcasts about Checkmate

In today's episode, we spoke with David Carbone, MD, PhD. Dr Carbone is a professor of internal medicine at The Ohio State University, co-leader of the Translational Therapeutics Program and director of the Thoracic Oncology Center at the Ohio State University Comprehensive Cancer Center–James, as well as the Barbara J. Bonner Chair in Lung Cancer Research in Columbus.In our exclusive interview, Dr Carbone discussed the 6-year data from the phase 3 CheckMate 9LA trial (NCT03215706), which not only reaffirmed the durability of benefit with nivolumab (Opdivo) plus ipilimumab (Yervoy) and chemotherapy but also highlighted particularly strong outcomes in historically poor-prognosis subgroups, including patients with PD-L1–negative tumors and those with squamous histology. Carbone also underscored the safety and tolerability of the regimen. Although dual immunotherapy carries higher toxicity than monotherapy, no new safety signals emerged at 6 years. Carbone also addressed the limitations of current biomarkers. Although PD-L1 remains the primary tool guiding immunotherapy decisions, it is an imperfect predictor. 

Dr. Lakshmi Rajdev and Dr. Manish Shah join the podcast to discuss the updated guideline on immunotherapy and targeted therapy in unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. They share first-line and subsequent-line recommendations for both gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma based on actionable biomarkers including PD-L1 expression, MMR and/or MSI, CLDN18.2 expression, and HER2 status. They note the importance of the algorithms and tables in the guidelines that provide visual illustrations and quick reference guides of the evidence-based recommendations. They also comment on ongoing and recently presented trials that may impact future guidelines in this space. Read the full guideline, "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update" at www.asco.org/gastrointestinal-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02958      Timestamps ·       00:00 – 02:15 Introduction and Overview ·       02:16 - 08:20 First-line treatment for patients with pMMR/MSS, HER2-negative gastroesophageal adenocarcinoma ·       08:21 –10:29 First-line treatment for patients with pMMR/MSS, HER2-positive gastroesophageal adenocarcinoma ·       10:30 – 14:39 First-line treatment for patients with dMMR/MSI-H, gastroesophageal adenocarcinoma ·       14:40 – 18:03 First-line treatment for ESCC ·       18:04 – 22:04 Second- and third-line therapy for gastroesophageal adenocarcinoma and ESCC ·       22:05 – 24:38 Importance of guideline ·       24:39 – 27:45 Outstanding questions and future research   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.   My name is Brittany Harvey, and today I am interviewing Dr. Lakshmi Rajdev from the Icahn School of Medicine at Mount Sinai and Dr. Manish Shah from Weill Cornell Medicine, co-chairs on "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update." Thank you for being here today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you for having us. It is wonderful. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Rajdev and Dr. Shah, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into what we are here today to talk about, Dr. Shah, I would like to start first with what prompted the update to this guideline, which was previously published in 2023, and what is the scope of this updated guideline? Dr. Manish Shah: Yes, terrific. So even in the last few years, the pace of drug development in gastroesophageal cancers has just been astounding. So, what prompted this guideline is actually the practice-changing results for a new biomarker, CLDN18.2 hat was based on the GLOW and SPOTLIGHT studies, as well as a practice-changing study in HER2-positive disease where we added pembrolizumab to trastuzumab and chemotherapy for tumors that are HER2-positive and PD-L1 CPS 1 or greater. And then there were also new studies and new approvals in esophageal squamous cell cancer that you will hear about as well. So there were several studies, overall more than 5,000 patients were reported on, and that led to several new therapies, new indications, and it really necessitated this guideline. Brittany Harvey: Excellent. It is great to hear about all of these exciting updates in this space. So then to next review the key recommendations of this guideline by clinical question that the expert panel addressed. So, Dr. Rajdev, what is the recommended first-line treatment for patients with proficient mismatch repair, microsatellite stable, HER2-negative gastroesophageal adenocarcinoma? Dr. Lakshmi Rajdev: Thank you for that question. So historically, we have sort of used fluoropyrimidine and platinum doublets, which yielded a survival of about one year. More recently, immunotherapy and targeted therapy options have improved outcomes in patients with advanced esophageal and gastric adenocarcinoma, as well as squamous cell carcinoma. Patients with gastric and GE junction adenocarcinoma have a high rate of actionable alterations, so it is imperative that physicians test the following biomarkers upfront so that it can help guide therapy. The markers recommended by the ASCO panel are HER2, MMR or MSI, CLDN18.2, and PD-L1. And also, it was recommended to use NGS if feasible in this patient population. HER2, as we know, is expressed in about 15% to 25% of patients; PD-L1 expression occurs in about 80% of patients; MSI-high, deficient MMR is present in about 5% to 8% of patients; and CLDN18.2 expression is present in about 40% of patients. There is, of course, biomarker overlap. About 13% to 22% of CLDN18.2 patients are also PD-L1 positive. For patients with pMMR or microsatellite stable HER2-negative disease with PD-L1 expression greater than 1 and absence of CLDN18.2, the panel recommended a first-line therapy with fluoropyrimidine and platinum-based therapy in combination with immunotherapy. These recommendations stem from large phase 3 trials, and the agents approved in the United States are pembrolizumab, nivolumab, and tislelizumab. It has been shown that immunotherapy benefit is greater in patients with higher PD-L1 expression, and it is not possible to comment on the individual PD-L1 cutoff scores and sort of identify the optimal PD-L1 cutoff score that sort of balances benefits and harms. But what is recommended is that immunotherapy-based treatments can be offered in patients with a CPS score of greater than 1. With regard to the choice of immunotherapy agents, that is pembrolizumab, nivolumab, or tislelizumab, these agents are considered to have similar efficacy, and the selection of an agent could be based on dosing schedule, cost considerations, toxicity, and the method of administration. Typically, clinicians should avoid withholding the start of chemotherapy while awaiting biomarker testing, depending on the clinical scenario. Now, for patients with pMMR microsatellite stable disease that is HER2-negative with PD-L1 expression less than 1 and positive CLDN18.2 expression, zolbetuximab-based treatments or in combination with chemotherapy is recommended, and this is based on two global phase III randomized controlled trials, the GLOW and the SPOTLIGHT. And across both studies, the hazard ratio for the overall survival was 0.78, and similarly, there was also an improvement in progression-free survival favoring the zolbetuximab group compared to the chemotherapy group alone. An important note is that nausea, vomiting is commonly associated with zolbetuximab-based treatments, and the panel recommended prophylactic antiemetics, adjusting zolbetuximab infusion rates, pausing infusion temporarily, using non-prophylactic antiemetics, and hydration intravenously prior to discontinuation of zolbetuximab-based chemotherapy. So effective handling of the GI-related symptoms with zolbetuximab is recommended prior to discontinuation of therapy. Now, for patients with pMMR microsatellite stable HER2-negative gastric, GE junction adenocarcinoma with PD-L1 expression greater than 1 and CLDN18.2 positivity, the ones with the dual expression with CLDN18.2 as well as PD-L1 chemotherapy, the choice of therapy can be based on the degree of PD-L1 expression, the toxicity profile, the burden of symptoms, and the anticipated improvement in symptoms associated with response to treatment, the patient comorbidities, the prior medical and treatment history. So this decision needs to be made on a case-by-case basis, and these are some of the factors that we suggested that could potentially influence the choice of therapy. For patients with pMMR microsatellite stable disease that is HER2-negative and a PD-L1 expression less than 1 and an absence of CLDN18.2 expression, first-line therapy with fluoropyrimidine and platinum-based chemotherapy is recommended. So you can see we have segmented out patients based on PD-L1 expression, pMMR and microsatellite stable disease expression, and also based on CLDN expression. Brittany Harvey: Absolutely. And that first point you noted, I think is really important, that biomarker testing is really critical for treatment decision-making in this space. So then the next subgroup of patients that the panel looked at, Dr. Shah, what first-line therapy is recommended for patients with proficient mismatch repair, microsatellite stable, HER2-positive gastroesophageal adenocarcinoma? Dr. Manish Shah: So this was an update from a few years ago. So we have known for 15 years now that if you are HER2-positive, you should get trastuzumab plus chemotherapy. That was based on the ToGA trial. And the update now is based on a trial called KEYNOTE-811, where it examined the addition of pembrolizumab to trastuzumab and chemotherapy versus trastuzumab and chemotherapy, and there was a progression-free and overall survival benefit. And again, here, the biomarkers are important. If your CPS PD-L1 is less than 1, we would not recommend Pembrolizumab in that setting, so you would still get trastuzumab and chemotherapy. But if it is 1 or greater, the PD-L1 CPS score, then we do recommend pembrolizumab unless there is a contraindication to immunotherapy. The take-home message really is from the onset of diagnosis, please check your biomarkers. And I will just, it is worth repeating, it is important to check your PD-L1 status, HER2 status, mismatch repair status, and CLDN18.2 status. And then the optimal therapy, and it is outlined in the publication, is really biomarker-driven. We know that if we are able to hit the target that is overexpressed, we are going to have a better outcome. And Dr. Rajdev did mention where there is overlap, there can be a lack of data, and that is where we are with both PD-L1 positive and CLDN positive. Here we do have data in HER2-positive cases where if you are both HER2-positive and PD-L1 positive, you would combine trastuzumab and pembrolizumab for the best outcomes. Brittany Harvey: Understood. I really appreciate you detailing what is most important for each individual biomarker combination that patients may have. So then following that, Dr. Rajdev, what does the expert panel recommend for first-line treatment for patients with esophageal squamous cell carcinoma that is not amenable to definitive chemoradiation? Dr. Lakshmi Rajdev: There are three phase III randomized clinical trials that have influenced practice in patients with esophageal squamous cell carcinoma examining the benefit of immunotherapy in this patient population. The RATIONALE-306 was a randomized trial of tislelizumab plus chemotherapy with platinum and fluoropyrimidine or paclitaxel versus placebo with chemotherapy. And then you have the KEYNOTE-590, which compared pembrolizumab plus chemotherapy versus chemotherapy alone. And then you have CheckMate-648, which included comparisons of nivolumab plus chemotherapy versus nivolumab plus ipilimumab or chemotherapy. And the primary endpoints for these studies were overall survival, and they did look at subgroups with PD-L1 expression. They used TPS score greater than 1% in CheckMate-648 and PD-L1 CPS greater than 10 in KEYNOTE-590. The bottom line is that the overall hazard ratio for overall survival across this patient population was 0.72. So clearly, there is benefit in patients that express PD-L1 CPS greater than 1 for benefit for the addition of immunotherapy. Now, the benefit again in patients with a PD-L1 expression less than 1 remains limited, and so the panel has made a recommendation for using immunotherapy in combination with platinum-based chemotherapy in patients with a PD-L1 greater than 1. Again, we know that it is hard to make recommendations on what PD-L1 cutoffs are recommended in this patient population, meaning that should it be limited to patients with a PD-L1 of 1 to 4 or greater than 10? I think that the general consensus that has been gleaned from the data is that the higher the PD-L1 expression, the greater the benefit. I do want to comment on another option that is available in patients with squamous cell carcinoma compared to adenocarcinoma, and that is the combination of nivolumab and ipilimumab. Now, in CheckMate-648, nivolumab with ipilimumab was also recommended as a treatment option in patients that have a PD-L1 score of greater than 1. There was a survival benefit demonstrated with this combination compared to chemotherapy alone. And an important observation in this study is that, although there was a slightly increased rate in early death, but there was really no significant difference in PFS and OS compared to chemotherapy alone. Importantly, the treatment appeared to be pretty well tolerated by the study population. There was a notable difference in the objective response rate, which was 35% in the nivolumab plus ipilimumab group compared to patients receiving nivolumab and chemotherapy, where it was 53%. So superiority is, so the importance of chemotherapy in patients with esophageal squamous cell carcinoma is to be noted. However, there is no difference in overall survival and progression-free survival when using the combination of nivolumab and ipilimumab, and thus it affords a chemotherapy-free option for this patient population with esophageal squamous cell carcinoma and a CPS with a score of greater than 1. Brittany Harvey: Understood. I appreciate you reviewing the evidence underpinning those recommendations as well. So then the next patient population that the guideline panel addressed, what first-line therapy is recommended for patients with deficient mismatch repair, microsatellite instability-high, gastroesophageal adenocarcinoma or esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: The rate of MSI-high expression is about 3% to 7% across different studies. Now, the KEYNOTE-158 was a tumor-agnostic study in patients with non-colorectal cancers, and again, the problem with the MSI-high population, given that it is so rare, the numbers in the individual studies are fairly small. But consistent outcomes do emerge, indicating high response to immunotherapy. So in KEYNOTE-158, a response rate of about 46% was noted. The number of patients was small, it was about 24. In CheckMate-649, which is a study of chemotherapy plus or minus nivolumab in patients with advanced gastric adenocarcinoma, there was again a very small number of patients, and patients that were MSI-high or deficient MMR did experience substantial benefits with the addition of immunotherapy, with hazard ratios in the order of about 0.38. In KEYNOTE-062, again, it was a very small number of patients, again about 6% or so, and similar to CheckMate-649, a substantial benefit was noted in combination with chemotherapy, but also there were benefits noted with pembrolizumab alone. The RATIONALE-305 again was a study of tislelizumab in combination with chemotherapy and similarly showed benefits to the combination of chemotherapy plus immunotherapy in this patient population. I think that we are all aware of the dramatic benefits of immunotherapy in this particular subset of patients, deficient MMR MSI-high, and also we have seen in CheckMate-649 they did have a subset of patients that received nivolumab and ipilimumab. And in this patient population, they noted unstratified hazard ratio of 0.28. So I think that the overall consensus is that immunotherapy is a very important treatment modality in patients with deficient MMR MSI-high disease, given that a lot of the trials in gastroesophageal adenocarcinoma have utilized chemotherapy-based options, that is certainly a recommendation of the panel to use chemotherapy in combination with immunotherapy. However, on a case-by-case basis, the panel recommended immunotherapy alone as well, and given the high response rates noted in trials across different diseases as well as noted in this disease as well. Brittany Harvey: Certainly. And I appreciate you both for reviewing these first-line recommendations. So moving to later lines of therapy, Dr. Rajdev, what recommendations did the expert panel make for second or third-line therapy for gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: So, I think that the RAINBOW trial that investigated the utility of the addition of ramucirumab as second-line therapy has been around since 2014, and those results have led to the addition of ramucirumab to taxane-based therapy in the second-line setting. Based on the utilization of oxaliplatin and platinum-based therapy in the front-line setting, there may be patients that have an underlying neuropathy, and so we wanted to really include treatment options for this patient population so that an agent that is less neurotoxic could also be recommended in combination with ramucirumab. The RAMIRIS trial is one such trial where ramucirumab was combined with FOLFIRI, and it demonstrated benefit in combination with ramucirumab. So we have listed that as a potential treatment option for patients in the second-line setting who may have an underlying neuropathy or even for whatever reason that based on the toxicity profile, that needs to be the preferred option by a physician, that recommendation is new from the older guidelines that we have. With regard to the utility of PD-1 inhibitors, there really has been no benefit noted in the second-line setting with regard to overall survival or progression-free survival, so no recommendation is made for that option. I think an important study that has been recently presented is the DESTINY-Gastric04 trial, which really has been practice-changing and has led to the recommendation for trastuzumab deruxtecan in patients that have HER2-positive metastatic gastric or GE junction adenocarcinoma. Now, this is a phase III trial in patients who retained HER2-positive disease after progressing on front-line trastuzumab-based treatments, and the comparator for this trial was trastuzumab deruxtecan versus ramucirumab plus paclitaxel. There was significant improvement and progression-free survival in patients that received trastuzumab deruxtecan. The patients that were excluded from the trial are patients that have pulmonary problems, interstitial lung disease; that is one of the toxicities of this particular agent, and close monitoring and prompt initiation of therapy such as glucocorticoid treatment in patients who develop this toxicity was also highlighted by the panel. So to summarize, the new guidelines highlight the possibility of FOLFIRI plus ramucirumab as a second-line option and then trastuzumab deruxtecan as a later-line option in patients that still retain HER2 expression. And that is very important because the trial did retest patients whether they expressed HER2. As we know, in a substantial number of patients, there is downregulation of HER2, and there is emerging data that the benefit for subsequent HER2-directed therapies is best noted in patients that still retain HER2 expression. Brittany Harvey: Great. So as our listeners have heard, there are many recommendations and new treatment options for advanced gastroesophageal cancer. Dr. Shah, earlier you highlighted the importance of biomarker testing, but I would like to hear in your view, what is the importance of this guideline and how will it impact both clinicians and patients with gastroesophageal carcinoma? Dr. Manish Shah: So as we have discussed throughout this podcast, the treatment for gastroesophageal cancer, both adenocarcinoma and squamous cell cancer, is increasingly complex, increasingly biomarker-driven. And I think the value of the guideline is to place all of that into context. So it provides the data for why certain biomarkers are important, what therapies should be indicated. Not only that, but if you are able to review the guideline, it provides the details of each of these studies and summarizes them in a meta-analysis fashion to sort of give you the context, because sometimes the individual studies can be maybe a little bit discordant or confusing and the guideline attempts to harmonize all that. And then also, I think the tables are very, very interesting because they give you actual numbers in terms of how many patients over a thousand would this benefit or how many patients over a thousand would this cause harm in terms of nausea, vomiting, or other things like that. So it gives you context for helping clinicians and patients weigh the potential benefits of the novel treatment strategies against the potential adverse events. And then finally, the guideline does also provide an algorithm that you are able to follow based on the biomarkers, and those are in figures 4 and 5. So I think overall, it is a very comprehensive guideline. It intends to make more manageable a very complex subject, and you know, I really encourage our listeners to review it after listening to the podcast. Dr. Lakshmi Rajdev: If I can add to that, I think that what is also really good about the guidelines is there are quick summaries. So if someone is busy in the clinic, of course, there is the opportunity to review the data supporting the guidelines in great depth in the manuscript, but what is also really good is that there are good summaries. In the event that you are very busy, you can easily identify what the recommendations should be for that particular patient based on these summaries. Brittany Harvey: Absolutely. Listeners are encouraged to review the full guideline, including those tables and figures that may be more helpful when they are looking for something quick to look at in the clinic as well. So, as you both mentioned, there have been a number of recent practice-changing trials in this area. So I imagine there is still a lot of ongoing research as well. So Dr. Shah, what are the outstanding questions regarding treatment options for patients with locally advanced unresectable, advanced, or metastatic gastroesophageal carcinoma? Dr. Manish Shah: I think we touched upon it a little bit. The guidelines are based on the data available, and they are primarily examining one novel therapy with chemotherapy in a specific biomarker population. But as you know, the biomarkers are not either/or; you are not either CLDN18.2 positive or PD-L1 positive. A portion of patients could have dual biomarkers, and you know, I think that we are generating data on how to manage those patients. At the recent GI Symposium in January this year, the ILUSTRO trial was presented by Dr. Shitara, which looked at combining zolbetuximab and chemotherapy with immunotherapy for dual-positive biomarkers, and that is leading to a phase III study that has begun to enroll. So unanswered questions are: how do we manage dual-positive biomarkers? The other thing that was mentioned is that the current data for mismatch repair deficiency involve chemotherapy plus immunotherapy. Only squamous cell cancer is there a study with a positive non-chemotherapy kind of backbone, that is CheckMate-648 that Dr. Rajdev mentioned. As we move forward, it will be good to get data on non-chemotherapy options in certain biomarker-positive populations. And then finally, another update, which is likely to be practice-changing, is the HERIZON-GEA-01 study that looked at zanidatamab, which is another biparatopic antibody that targets HER2, and that is likely to change practice. And as that data gets published, we may look to even do a rapid update for the current immunotherapy and targeted therapy guideline that is just being published. Dr. Lakshmi Rajdev: So, if I can add to that, there are numerous ADCs that look very interesting. There are bispecific antibodies; in fact, the zanidatamab is a bispecific antibody showing improved activity in patients with HER2-positive disease. So I think there are studies from Asia looking at CLDN CAR T-based therapies. So, I think that there are a lot of novel agents and a lot of excitement in the field. We know that the bemarituzumab study, unfortunately, the FGFR2 inhibitor failed to demonstrate any benefit, but I think that there are other agents that are being explored, so there are newer targets, newer agents, ADCs, bispecifics that could potentially change the field in the future. Brittany Harvey: Yes, we will look forward to the data to address these unanswered questions and new agents and inform future guideline updates. So, I would like to thank you both for all of your work to review the evidence here and update this important guideline, and for your time today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

President Trump draws a stark contrast with the Democrats at the State of the Union; Ilhan Omar and Rashida Tlaib are the new faces of the Democratic Party, and that's an awful thing for the Democrats; and the media meltdown over Trump's big night. Ep. 2375 - - - Click here to join the member-exclusive portion of my show: https://dwplus.watch/BenShapiroMemberExclusive - - - Facts Don't Care About Your Feelings - - - Today's Sponsor: ZipRecruiter - Try ZipRecruiter FOR FREE: https://ZipRecruiter.com/DAILYWIRE - - - DailyWire+: Become a Daily Wire Member and watch all of our content ad-free: https://www.dailywire.com/subscribe

Mesothelioma can strike at any time, but it most commonly affects those in their 70s, with cases continuing well into the 2030s. The time from exposure to diagnosis can be up to 60 years. This week, we explore treatment options for pleural mesothelioma, including ipilimumab and nivolumab, and consider whether chemotherapy and bevacizumab work for mesothelioma as well. The MAPS trial was published in 2016, while Checkmate was published in 2022.Studies discussed in this episode:MAPSCheckmate 743For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

The Last Trade: On-chain analyst James Check (Checkmate) joins the crew to break down bitcoin's bear market capitulation, what the data says about where we are in the cycle, and why the obituaries being out might be the most bullish signal of all.---

America and Iran just held “talks” where they wouldn't even sit in the same room, all while Tehran publicly threatened to sink U.S. aircraft carriers. In this episode of Israel Undiplomatic, you'll learn how to read the real power dynamics behind the Geneva meeting: why delaying diplomacy can actually help the U.S. and Israel militarily, what Vice President J.D. Vance's “red lines” signal about where Washington is headed, and why PM Netanyahu's two non-negotiables (removing enriched uranium and ending Iran's ability to enrich at all) expose the “peaceful program” claim as a bluff. The hosts also clash over the biggest strategic dilemma: is any deal enforceable with an ideological regime or does a “good deal” just buy the Ayatollahs time to rebuild, fund proxies and outwait the West?

Reality Checkmate by Daniel Ruiz by Poets & Writers

Sintonía: "Trailer Music" - Javi Pez (adaptación libre de "Trailer Music" de los Pizzicato Five 1.- Teardrop (Mad Professor Mazaruni Vocal Mix) 2.- Euro Zero Zero 3.- Group Four (Mad Professor Remix) 4.- Inertia Creeps (State Of Bengal Mix) 5.- Reflection (Mixed by Andy) 6.- Face a la mer (Massive Attack Remix) - Les Negresses Vertes 7.- Drum & Base In The Asylum - Mad Professor 8.- Checkmate! - Mad ProfessorRelación de fechas de emisión de los 4 anteriores programas de este coleccionable: 1.- Emitido el 03/09/2025: Blue Lines (1992) y Protection (94) 2.- Emitido el 16/10/2025: Mezzanine (98) y 100th Window (03) 3.- Emitido el 22/12/2025: Heligo Land (10) y Singles 90-98 (1ª Parte) 4.- Emitido el 13/01/2025: Singles 90-98 (2ª Parte)Escuchar audio

Talking about the inter workings of the government and what is true and what is smoke and mirrors. Is this administration truly lost, or strategically setting the opposition up for a Checkmate move??The SAVE Act is still being hotly debated and passed the House only with a tie breaking vote. It's my belief that without nuking the filibuster it will never pass the Senate… What say you?Epstein files news of course as more information comes out. List of names etc.. unfortunately still no realistic accountability More random points of information and opinions!!Until Next Time…

Democrats didn't imagine that getting access to the Epstein files meant that their searches were being monitored; now they're claiming (yet again) an abuse of power by Team Trump. Also on the show: The myth of the split-ticket voter, and more good news about the economy.

Warning: SPOILERS! If you haven't read “The Murder of Roger Ackroyd,” do yourself a favor and stop here and read it. You'll thank us later.“Checkmate” (2022) is the first official adaptation of Agatha Christie's stories. Situ Yan is an idealistic lawyer and when behind-the-scenes machinations sets an assassin free (think “Murder on the Orient Express”), he's left holding the bag. His train trip to Harbin in Manchuria is eventful and after befriending the soldier Luo Shaochuan (think Hastings), they find themselves investigating murders, kidnappings, stolen dogs, and other crimes.“Checkmate” is a 24-episode telenovella that covers “Orient Express,” “The Murder of Roger Ackroyd” (the subject of today's livestream), “One, Two, Buckle My Shoe,” “Three Act Tragedy,” “The Nemean Lion,” “Curtain,” and more!Teresa Peschel, author of "Agatha Christie, She Watched" and the "International Agatha Christie, She Watched," hosts our livestream. Joining Teresa is her husband, technical adviser, and straight man, Bill Peschel. Together, they are Peschel Press, publisher of intriguing, intelligent, and idiosyncratic books (www.peschelpress.com).HOW TO SEE THIS MOVIE: Links: iQIYI website (login needed) https://www.iq.com/album/checkmate-2022-1vwjz1u3j1p?lang=en_usDVD versions for sale on eBay: https://www.ebay.com/sch/i.html?_nkw=checkmate+dvd+chinese+seriesPeschel Press: www.peschelpress.comInstagram: https://www.instagram.com/peschel_press/NEXT WEEK:We're jumping ahead to “The Seven Dials Mystery.” We're watching first the James Warwick version from 1981 and discussing it on 1/22/26. Then, on Jan. 29, we'll tackle the new Netflix adaptation.

Mary welcomes John Haller back to the conversation – and with his extensive understanding of the Middle East we always come away seeing things a bit more clearly. Today is no exception. John has dug deep into the weeds of what is going on over there and “complex” doesn’t begin to cover it at all. October 7, 2023 seems to have ushered in a new world over there (and over here) with a multi-layered event that has resulted in clarity about the players, their demonic hatred for the Jews, and the depths of antisemitism that have laid down a new normal around the world. Continuing down the hole, we have a wounded Iran ready to do whatever they want to bring chaos and violence to a new level. Also rising to the top are new players with hopeful new influence such as Turkey, Qatar, Syria, Oman, the UAE and more. All of a sudden it’s true globalism, and Trump is contributing to it greatly by bringing as many nations as possible to the table. What could possibly go wrong? Things are happening at an astonishing pace, and we are here to see it all unfold. Pray for wisdom, grace, and eyes to see, ears to hear. Stand Up For The Truth Videos: https://rumble.com/user/CTRNOnline & https://www.youtube.com/channel/UCgQQSvKiMcglId7oGc5c46A

 Bitcoin whipsawed violently, including what the hosts describe as the largest one-day drop in Bitcoin's history in nominal dollar terms, followed by a sharp reboundCore message: “check your conviction,” widen your time horizon, and avoid leverage (options + liquidations are highlighted as the two classic ways people get forced out)Checkmate's “bull case” framed around Bitcoin as a 10x technological improvement and the unusually high-quality, diverse cohort of people attracted to BitcoinJames Lavish's “knowledge arbitrage” thesis: most allocators still don't understand Bitcoin, and that gap will close as institutions normalize it as a core assetSaylor clip reinforces that drawdowns are a recurring feature of an emergent asset and often flush out leverage/touristsThe hosts call out media “grave-dancers,” focusing on Paul Krugman's critique and the inconsistency of dismissing Bitcoin for lacking earnings while holding up gold as the refuge assetA major working hypothesis for the crash: forced selling from leveraged entities or hedge-fund unwind dynamics (Jeff Park referenced), rather than a clean “fundamentals changed” storyCrypto-industry capitulation is framed as short-term collateral damage but long-term bullish for Bitcoin (Pierre Rochard: crypto narratives slowed Bitcoin adoption)Lightning milestones: a $1M payment reportedly routed via Lightning (Voltage), plus Steak 'n Shake's claim of faster checkout and ~50% fee savings vs cards, with measurable transaction share impactQuick-hit morale boosters: Gene Simmons posts HODL/DYOR support; reminder that Bitcoin's adoption and infra keep compounding despite price chaos  ► For high-net-worth individuals and corporations seeking to build generational wealth with Bitcoin, Swan Private is your guide ✔ https://www.swanbitcoin.com/private?utm_campaign=private&utm_medium=sponsorship&utm_source=podcast&utm_content=swan_signal_live ► Secure your bright orange future with the Swan IRA today! Real Bitcoin, no taxes ✔ https://www.swanbitcoin.com/ira?utm_campaign=ira&utm_medium=sponsorship&utm_source=podcast&utm_content=swan_signal_live ► Secure your Bitcoin with Swan Vault ✔ https://www.swanbitcoin.com/vault?utm_campaign=vault&utm_medium=sponsorship&utm_source=podcast&utm_content=swan_signal_live ► Download the all-new Swan Bitcoin App ✔ https://www.swanbitcoin.com/app?utm_campaign=app&utm_medium=sponsorship&utm_source=podcast&utm_content=swan_signal_live ► Want to learn more about Bitcoin? Check out Welcome To Bitcoin a FREE Introductory course. Learn about Bitcoin in under 1 hour! ✔ https://www.swanbitcoin.com/welcome?utm_campaign=welcome_to_bitcoin&utm_medium=sponsorship&utm_source=podcast&utm_content=swan_signal_live ► Connect with Swan Bitcoin: ✔ Twitter: https://twitter.com/Swan ✔ Instagram: https://instagram.com/SwanBitcoin ✔ LinkedIn: https://linkedin.com/company/swanbitcoin ✔ Threads: https://www.threads.com/@swanbitcoin ✔ Facebook: https://www.facebook.com/SwanBitcoin/ ✔ TikTok: https://www.tiktok.com/@realswanbitcoin

The Huntress Podcast is back to talk about the final installment of the Checkmate vs. Huntress saga within the pages of Gotham Knights #40.   Write to us at feathersandfoes@gmail.com We would love to hear from you.  We would also like to hear from you if you read Batman: Gotham Knights back in the day.   www.patreon.com/wrightonnetwork  

I am excited to chat with Greg Davis on the game of life we call Chess and how to get to your Checkmate. Greg holds numerous certifications, is retired as an award-winning professor of accounting at the prestigious University of Illinois and senior finance executive at Hershey Entertainment & Resorts, the world-renowned entertainment company based in Hershey, PA. With a unique perspective, he has been successful in both the corporate world and in academia. Greg currently lives in Philadelphia with his wife, Abby, of 34 years and enjoys spending time with family and doing activities together with Abby. Greg enjoys bicycling and walking around the city. True to the name of his book, CHECKMATE, Greg also plays a lot of chess. He also enjoys sharing his knowledge of personal finance and retirement by writing articles as a freelance writer. #communication #checkmate #chessconnect with sifu sifurafael.com

In this episode I give a musical middle finger salute to the former leader of ICE here in Minneapolis, Greg Bovino.  The Ballad of Bovino, with lyrics by me, music by AI, is just the song these perilous times demand.  You can't dance to it but you couldn't dance to Masters of War or Eve of Destruction, either.  The kids won't sing along to it in the minivan and you yourself may only want to hear it once but it's certainly good enough for one spin.  The Vermont woman whose husband started dressing like a dime store cowboy took my advice and she got back in touch to tell me how it went.  How serious of a crime could someone be guilty of and you'd still want to marry them?  I help a client figure it all out with my new app Check Mate, a quiz to give a prospective partner before committing.  Another new client is worried space aliens will find us and make us slaves.  I try to provide guidance on what to do when they get here.  It's all over in under 20 minutes.  What do you have to lose?  Subscribe and THRIVE!!!!

Checkmate.Huge shoutout to Pranav (IG:  @chesseswar ) for hopping on the podcast. Let us know if you want us to bring him back!Branding: @JessicaShenCheck Us Out!YouTube ►⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@statingtheobviouspodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠All Our Links ►⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/statingtheobvious⁠⁠⁠⁠

OPINION: Impeachment checkmate | Jan. 31, 2026Subscribe to The Manila Times Channel - https://tmt.ph/YTSubscribeVisit our website at https://www.manilatimes.net Follow us: Facebook - https://tmt.ph/facebook Instagram - https://tmt.ph/instagram Twitter - https://tmt.ph/twitter DailyMotion - https://tmt.ph/dailymotion Subscribe to our Digital Edition - https://tmt.ph/digital Check out our Podcasts: Spotify - https://tmt.ph/spotify Apple Podcasts - https://tmt.ph/applepodcasts Amazon Music - https://tmt.ph/amazonmusic Deezer: https://tmt.ph/deezer Stitcher: https://tmt.ph/stitcherTune In: https://tmt.ph/tunein#TheManilaTimes Hosted on Acast. See acast.com/privacy for more information.

-Rob celebrates Tom Holman's arrival in Minneapolis, declaring the hippies confused, ICE-hating, and running out of things to protest. -Rep. Mike Collins appears on the Newsmax hotline, diving into FBI raids, election distrust, illegal immigration, and the eternal battle between Crystal Burger and White Castle. Today's podcast is sponsored by : RELIEF FACTOR - You don't need to live with aches & pains! Reduce muscle & joint inflammation and live a pain-free life by visiting http://ReliefFactor.com  BIRCH GOLD - Protect and grow your retirement savings with gold. Text ROB to 98 98 98 for your FREE information kit! To call in and speak with Rob Carson live on the show, dial 1-800-922-6680 between the hours of 12 Noon and 3:00 pm Eastern Time Monday through Friday…E-mail Rob Carson at : RobCarsonShow@gmail.com Musical parodies provided by Jim Gossett (http://patreon.com/JimGossettComedy) Listen to Newsmax LIVE and see our entire podcast lineup at http://Newsmax.com/Listen Make the switch to NEWSMAX today! Get your 15 day free trial of NEWSMAX+ at http://NewsmaxPlus.com Looking for NEWSMAX caps, tees, mugs & more? Check out the Newsmax merchandise shop at : http://nws.mx/shop Follow NEWSMAX on Social Media:  -Facebook: http://nws.mx/FB  -X/Twitter: http://nws.mx/twitter -Instagram: http://nws.mx/IG -YouTube: https://youtube.com/NewsmaxTV -Rumble: https://rumble.com/c/NewsmaxTV -TRUTH Social: https://truthsocial.com/@NEWSMAX -GETTR: https://gettr.com/user/newsmax -Threads: http://threads.net/@NEWSMAX  -Telegram: http://t.me/newsmax  -BlueSky: https://bsky.app/profile/newsmax.com -Parler: http://app.parler.com/newsmax Learn more about your ad choices. Visit megaphone.fm/adchoices

Glenn looks at the latest in Minnesota and breaks down who's behind all the riots and chaos happening within that state. Glenn analyzes President Donald Trump's "Art of the Deal" and how he utilized his dealmaking method when discussing immigration with Minnesota Governor Tim Walz (D). Glenn breaks down how the current unrest in Minnesota is an insurrection that calls for the ultimate authority to act. Glenn and Stu discuss Stu's last week on Glenn's show and hint at what Stu is doing next. Glenn and Jason discuss the shooting of Alex Pretti and explain how the Left's rhetoric regarding ICE actions is to blame for the recent tragedy. Data expert DataRepublican joins Glenn to discuss the far-left Minneapolis Signal chat used to track down ICE agents, which also allegedly includes potential foreign involvement. Glenn and Stu share what each will miss the most when Stu is no longer on "The Glenn Beck Program."  Learn more about your ad choices. Visit megaphone.fm/adchoices

Trump Checkmate Complete - India EU Defense & Trade Pacts are Massive | Iran | MajorToor, VibhutiJha

Can there be love where there is no trust? Can Kennedy and Relic come back from the things they've done to each other? On tonight's episode of BGBCP, we discuss this and so much more. Take a listen.Larenn.The Queen.She came. She saw. She conquered the one man whose heart seemed impenetrable—Relic Blaise.Read Respectfully, Kennedy (Checkmate: Dyab Je Ble vs Larenn Book 2): https://www.amazon.com/dp/B0GFXV2SG5/ref=sr_1_1?crid=3VE7OFBBQXPRT&dib=eyJ2IjoiMSJ9.xOK6DZjzr6x-CCYxCpWp5VGlxILjeltPxzgdkRbLQOF_TpPRpkg6cyW3bsE0yRQM8ldUYZWt1saSj14Q3IZYMn3MPLhMSF6FjQZj0VLbrwAuS75RsT_hSvgxToGWJpr7gRFHs20R5m2k9n2iGMlYg9jxxnBjbWn0mtIpWGJVhK_mJcNedz8HSHzxWgmLRyAPZt-qS_XqqcCEJlOLO7w4Fwu-TPtWwYsrzhBgqHkYVRc.Ut9KTwfAMwnDxsUV4OjvQPk8_O9U_P136JziC50JxYI&dib_tag=se&keywords=antoinette+sherell&qid=1768232094&s=digital-text&sprefix=antoin%2Cdigital-text%2C182&sr=1-1Connect with Author  Antoinette Sherell: https://www.instagram.com/still_trappdn_mynett/Your Book Bae Awaits at theblackgirlbookclub.comJoin the Black Girl Book Club Podcast Community: https://www.facebook.com/groups/theblackgirlbookclubpodcastJoin the Black Girl Book Club Podcast Email list: https://www.theblackgirlbookclubpodcast.com/theblkgrlbcpodcast-6136Listen to Apple: https://podcasts.apple.com/us/podcast/the-black-girl-book-club-podcast/id1627300394This episode is brought to you by Just Write Sis, the Authors organization solution. Are you an author who's ready to start running her writing business like a business, implementation strategy, systems, and automation. Increasing your rating, readership, and engagement. Check out Just Write Sis, the marketing and systems strategist for authors. www.justwritesis.com#bookdiscussion #blackromancenovel #theblackgirlbookclubpodcast #bookclub #blackbookclub #blackgirlswhoread #justwritesis #theauthorsstrategist #Antoinette Sherell #RespectfullyKennedy #DisrespectfullyRelic

LTPetClub: http://ltpetclub247.com Support your body's immune response sand immune system functions today ——— Protect your investments with And We Know http://andweknow.com/gold Or call 720-605-3900, Tell them “LT” sent you. ————————— AT sea with LT. 2026. Caribbean: https://www.inspirationtravel.com/event/lt-caribbean-cruise-2026 ————————— ➜ Our AWK Website: https://www.andweknow.com/ ➜ AWK Shirts and gifts: https://shop.andweknow.com/ ——  *DONATIONS SITE: https://bit.ly/2Lgdrh5 *Mail your gift to: And We Know 30650 Rancho California Rd STE D406-123 (or D406-126) Temecula, CA 92591 ➜ AWK Shirts and gifts: https://shop.andweknow.com/ ➜ Audio Bible https://www.biblegateway.com/audio/mclean/kjv/1John.3.16 Connect with us in the following ways: + DISCORD Fellows: https://discord.gg/kMt8R2FC4z

Protect Your Retirement with a PHYSICAL Gold and/or Silver IRA https://www.sgtreportgold.com/ CALL( 877) 646-5347 - You Can Trust Noble Gold Having grown up in an atheist family independent media analyst Patty V decided to convert to Judaism several decades ago, and while Patty and I don't see eye to eye on the genocide in Gaza, we do see much of everything else the same way: Humanity is in grave danger as the Zionist entity entrenches western governments with their Rothschild tentacles of endless war, endless debt and death. We discuss Charlie's assassination, the attempted character assassination of Candace Owens, and much more. Thanks for tuning in.   Get the EVIL SHIT OUT of your body! Remove heavy metals, graphene oxide & nanotech from your blood w/ MaterPeace: https://masterpeacebyhcs.com/?ref=4094   Get PHYSICAL precious metals HERE w/ FREE shipping on orders over $199 https://sdbullion.com/gold-silver-ira?utm_source=sgtreport https://rumble.com/embed/v71skle/?pub=2peuz

They told you it was about narco-terrorism. They told you it was about justice. They lied. The capture of Venezuelan dictator Nicolás Maduro isn't just a win for the DEA—it is a geopolitical earthquake involving oil, gold, silver, the war on terror, and a battle for global supremacy. In this explosive episode of Keeping It Real, Jillian Michaels sits down with Ex-CIA Covert Ops Officer Mike Baker (host of The President's Daily Breif) and Constitutional Attorney Josh Hammer to reveal what the mainstream media and partisan pundits aren't telling you. We strip away the headlines to expose the truth about what's really going on, why, and what is likely to happen next:

In this episode of the Measure Success Podcast, Carl J. Cox sits down with John Whitt, founder of Business Whitt and author of Checkmate, to explore how strategic thinking, leadership, and generosity intersect. John explains how lessons from competitive chess apply directly to business. Small advantages, disciplined execution, and resource placement matter more than chasing quick wins. The conversation covers clarity in goal setting, identifying constraints, testing ideas before scaling, and leading with generosity as a competitive edge. Listeners will gain practical insight into building strategy that holds up under pressure and leadership habits that create lasting results. Listen now and learn how to think ahead, execute with intention, and lead in a way that drives sustainable success.  

Hello and welcome to Farm to Fable, a Smallville re-watch fancast. Here is our review/discussion of s9 ep 20 Sacrifice . This episode was originally aired on April 30th, 2010. It was written by Justin Hartley, Walter Wong and Bryan Q. Miller and was Directed by Kevin Fair. Episode summary: Clark tries to keep Chloe and Lois out of harm’s way by recruiting Green Arrow to help him track down Zod.  Tess invites herself and inadvertently Checkmate to watchtower putting both of their lives at risk and ultimately Tess' life in Chloe’s hand. Checkmate declares war on the Kandoraians and Zod burns them down. Faora dies and takes with her the last hope of Clark and Zod living peacefully together on earth. It's IMDB.com rating 8.2 PASS THE TORCH QUESTION:   What value would you bring to a relationship with a Super-hero? In this episode Michael is joined by Chris Goffredo Mentioned on the show I Used to Like This One Podcast Tabletop Journeys Podcast and Youtube Channel Subscribe to The RPG Academy Youtube channel to support Michael Support Michael on Patreon Like and follow our Facebook page Smallville Farm to Fable Subscribe and leave us a review on Apple Podcasts. Smallville: Farm to Fable E-mail us any comments/concerns/questions to SmallvilleFancast@gmail Thank you for listening and we hope you'll follow along as we discuss each episode in the future. Thanks!! Michael

Today we talk about Sasha Bordeaux, who was hired to be Bruce Wayne's bodyguard, figured out he was Batman, and then ended up joining Checkmate and becoming a cyborg. What we were up to this week: Briar was mostly just reading more Robin Hobb and getting ready to go to ALA Olivia received Spectators for Christmas but hasn't had time to read it yet! Thanks to Victoria Watkins for our icon! Support Capes and Japes by: Checking out our Patreon or donating to the Tip jar Find out more on the Capes and Japes website.

https://www.tiktok.com/@grizzled_takes?lang=en https://www.tiktok.com/@malenky10?lang=en https://fydpodcast.podbean.com/ Facebook - www.facebook.com/foryourdistraction feeds.feedburner.com/foryourdistraction https://www.patreon.com/ForYourDistraction YouTube - www.youtube.com/channel/UCuEgNqvW…JPRHxHrA/featured For Your Distraction is a member of the Electronic Media Collective! To listen to us and more great shows head to electronicmediacollective.com/distraction/

Join Lionel on The Other Side of Midnight for a provocative masterclass in political realism and constitutional law. In this episode, Lionel dissects the recent military operation to remove Nicholas Maduro in Venezuela, challenging the popular narrative that such actions are unconstitutional without a formal declaration of war. Moving beyond "bumper sticker" politics, he explores why international relations are governed by power rather than morality, the historical precedent of presidential force, and why the Constitution was designed for executive speed and secrecy. It's a blunt, didactic look at global reality, "sweet" Venezuelan oil, and why, in a world of anarchy, there is no 911 for nation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Join Lionel on The Other Side of Midnight for a provocative masterclass in political realism and constitutional law. In this episode, Lionel dissects the recent military operation to remove Nicholas Maduro in Venezuela, challenging the popular narrative that such actions are unconstitutional without a formal declaration of war. Moving beyond "bumper sticker" politics, he explores why international relations are governed by power rather than morality, the historical precedent of presidential force, and why the Constitution was designed for executive speed and secrecy. It's a blunt, didactic look at global reality, "sweet" Venezuelan oil, and why, in a world of anarchy, there is no 911 for nation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Hour 1 of The Big Show with George Rusic and Brent Krahn is on demand! To kick off the show, George makes his return! Then the guys get right into Canada's Semifinal loss at the hands of Czechia at eh World Juniors last night. George and Krahner give their takes on their frustrations with Canada's game and tournament as a whole.(20:59) Later on, Shan Virjee gets you all caught up on the world of sports in the Morning Report!The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate. Get full Flames games and great shows like Quick 60: The Stamps Show, Wranglers Watch and more ON DEMAND.

Position Exercise: The audio will tell you where each of the pieces on the board are and whose turn it is. Find the best move! To learn more about Don't Move Until You See It and get the free 5-day Conceptualizing Chess Series, head over to https://dontmoveuntilyousee.it/conceptualization FEN for today's exercise: B5KR/1r5B/6R1/2b1p1p1/2P1k1P1/1p2P2p/1P2P2P/3N1N2 w - - 0 1 And the answer is... Rc6+ From the book "Totally Puzzled" by John Herron.

The Huntress Podcast is back to talk about Helena Bertinelli in the pages of Batman: Gotham Knights, where the secret government agency, Checkmate, is using some invasive techniques to coerce The Huntress into being their Queen, which could also lead the organization to The Batman.   e-mail us at feathersandfoes@gmail.com Visit our website: https://wrightonnetwork.libsyn.com/website www.patreon.com/wrightonnetwork    

Hello and welcome to Farm to Fable, a Smallville re-watch fancast. Here is our review/discussion of s9 ep 17 Checkmate . This episode was originally aired on April 9th, 2010. It was written by John Chisolm and was Directed by Tim Scanlin. Episode summary: Martian Manhunter confronts checkmate solo trying to protect Clark and the rest of the proto-JLA from checkmate but when Green Arrow and then Chloe are captured Clark is forced to intervene revealing himself to Waller.    It's IMDB.com rating 8.0 PASS THE TORCH QUESTION:   If you could have Smallville make an homage to another TV show, which would it be? In this episode Michael is joined by Chris Goffredo Mentioned on the show I Used to Like This one Podcast Tabletop Journeys Podcast and Youtube Channel Subscribe to The RPG Academy Youtube channel to support Michael Support Michael on Patreon Like and follow our Facebook page Smallville Farm to Fable Subscribe and leave us a review on Apple Podcasts. Smallville: Farm to Fable E-mail us any comments/concerns/questions to SmallvilleFancast@gmail Thank you for listening and we hope you'll follow along as we discuss each episode in the future. Thanks!! Michael

BITCOIN CHECKMATE! The crypto market is entering a MAJOR turning point — and most traders have no idea what's about to hit.

In this special edition of the Best Science in Lung Cancer series, host Erin Gillaspie, MD, sits down with Brendon Stiles, MD, to discuss insights from ASCO, including perioperative immunotherapy, CheckMate 816, and expanding surgical boundaries.

Secretary of Defense Hegseth is making use of his sights.  He is focusing at times on Senator Mark Kelly, seeking to wreak havoc upon him for his utterances which have angered Hegseth's master.  Meanwhile, purported drug smugglers have found Davy Jones' locker at the order of Hegseth, it has been reported, including those left helpless after initial lethal strikes.  Yale Professor and Bancroft Prize winner John Fabian Witt joins us to help us make sense of the international law and laws of war issues here. Meanwhile, your poor co-host, Andy, is subjected to a Socratic barrage at the hands of a Kingsfield-like Professor Amar, as the relentless logic - or is it illogic - of Hegseth's actions run into a Constitutional wall.  This is an entirely new, and entirely irresistible analysis; it's Professor Amar at his best. CLE credit is available for lawyers and judges from podcast.njsba.com.

The Listing Bits Podcast is now available on your favorite podcast player! Overview Greg sits down with returning guest Annie Ives, CEO of CLAW/The MLS™, to discuss major industry changes following NAR policy shifts, the rise of MLS-only memberships, exclusive-listing strategies, and the rapid growth of CLAW's in-house technology products including Vesta Plus, Checkmate, Showing software, and MarketSnap. Annie also shares insights on managing a high-end market, delivering strong customer service, and the future role of MLSs in a shifting industry. Key Takeaways NAR's policy changes are already increasing MLS-only membership interest, especially in California's Thompson state environment. Annie expects MLS-only membership to rise from ~15% to potentially 25–30% as agents look to cut costs. Associations may face pressure to restate their value proposition as non-dues revenue becomes increasingly important. CLAW is launching a new listing status: MLS Exclusive — allowing listings to remain off-market-facing while still visible to MLS members. MLS Exclusive listings accrue no DOM and no public price-change history while in that status. CLAW continues to grow its in-house technology stack, including: Vesta Plus MLS platform Checkmate compliance software (now used by ~200k agents) Showing software MarketSnap analytics Annie credits their success to customization, rapid iteration, and client-driven feature development. She predicts MLSs will increasingly become technology companies, especially as revenue from dues becomes less stable. Future industry direction remains uncertain, but Annie emphasizes persistence, adaptability, and building strong teams as core to longevity. Links: Vesta Plus – Request a demo   Sponsors Trackxi – Real Estate's #1 Deal Tracking Software Giant Steps Job Board – Where ORE gets hired Production and editing services by: Sunbound Studios  

The latest episode of Thinking Thoracic dives into one of the most challenging diseases in thoracic oncology—malignant pleural mesothelioma. Host Erin Gillaspie, MD, speaks with Joshua Reuss, MD, a thoracic medical oncologist and clinical trials leader, about how immunotherapy, evolving surgical strategies, and global practice patterns are reshaping care for this rare cancer. The episode covers the impact of the Checkmate 743 trial, controversy surrounding the MARS-2 surgical study, promising results from neoadjuvant immunotherapy trials, and the critical need for collaboration and clinical trial enrollment to drive progress. Listen now to explore where mesothelioma research is headed and what it means for patient care.

Sunday - 11/30/2025 - Dwayne Riner

The Huntress is kidnapped by Checkmate, who are trying to recruit her to join their organization/agency.  Forced under certain hallucinogens by the Mad Hatter and Scarecrow, the leader of Checkmate is trying to psychoanalyze Helena via her responses.  We know Helena is someone you can't make do anything.  Even placing her in a padded room with a one way window can't keep this woman in confinement.   Let us know what you thought about this issue and the Batman: Gotham Knights series as a whole at feathersandfoes@gmail.com https://wrightonnetwork.libsyn.com/website Bluesky: @huestone44 www.patreon.com/wrightonnetwork  

As the Zveno and Military League government focuses on implementing its reforms, it suddenly finds that it has been outplayed by an unlikely opponent. Supporters like you make this podcast happen! Check out www.patreon.com/bulgarianhistorypodcast to see the great perks you can get for supporting us. You can find images for this episode at: www.bghistorypodcast.com/post/244-checkmate Check out the book here: www.amazon.com/State-Builders-St…an/dp/6197814110/

Send us a textA dysfunctional group of friends run a radio show of some renown. The producer of the show attempts to innovate by creating a new ad to promote the show, which somehow ends up triggering a zombie outbreak. On Episode 693 of Trick or Treat Radio we discuss the Indonesian zombie flick The Elixir from director Kimo Stamboel! We also have a mini retrospective on James Gunn and his humble beginnings with Troma, we react to the very pretty trailer for the upcoming film Reflections in a Dead Diamond, and talk about trying to make your zombie movie stand out from the pack. So grab a bottle of magical elixir, RSVP to the circumcision party, and strap on for the world's most dangerous podcast!Stuff we talk about: Shout/Scream Factory, Gruv, Zohran is All Elite, welcome new listeners, The Mask of Fu Manchu, The Son of Dracula, Lon Chaney Jr., Demons of the Mind, Robocop 3, The Bone Collector, Alien Uprising, Christy, Red Letter Day, Basement Jack, Hansel and Gretel, Corin Nemec, The Green Mile, House on Haunted Hill, The Faculty, Lord of Illusions, Hemlock Grove, Robert Patrick, Terminator 2, The Faculty, Fire in the Sky, The Card Player, Manitou, Day of the Animals, Baron Blood, Lisa and the Devil, Ghostbusters 2, Henry Hall, The 13th Guest, The Peacemaker, John Cena, Tim Meadows, Man of Tomorrow, Checkmate, ignorance can hurt, James Gunn, Tromeo and Juliet, Lloyd Kaufman, Toxic Avenger IV: Citizen Toxie, Ron Jeremy, Lanterns, Reno 911, The State, Kerri Kenney, Joe Lo Truglio, Nick Swardson, Wet Hot American Summer, Sleepaway Camp, Super, Movie 43, RIP Diane Ladd, Stacey Keach, Reflections in a Dead Diamond, Helene Cattet, Bruno Forzani, Guy Fawkes, The Elixir, The Sadness, Train to Busan, Shaun of the Dead, Kimo Stamboel, The Jerk, Rob Jabbaz, Warm Bodies, Fido, Pontypool, The Battery, circumcision party, Mel Brooks, Dawn of the Dead, The Night Comes For Us, Spinal Tap, the old Castle Wolfenstein, Patreon Takeover, Evil Corny, Frankenberry, Guillermo del Toro's Frankenstein, Opus, The Elixir Initiative, and sitting on the edge of your toilet.Support us on Patreon: https://www.patreon.com/trickortreatradioJoin our Discord Community: discord.trickortreatradio.comSend Email/Voicemail: mailto:podcast@trickortreatradio.comVisit our website: http://trickortreatradio.comStart your own podcast: https://www.buzzsprout.com/?referrer_id=386Use our Amazon link: http://amzn.to/2CTdZzKFB Group: http://www.facebook.com/groups/trickortreatradioTwitter: http://twitter.com/TrickTreatRadioFacebook: http://facebook.com/TrickOrTreatRadioYouTube: http://youtube.com/TrickOrTreatRadioInstagram: http://instagram.com/TrickorTreatRadioSupport the show

What happens when your purpose gets weaponized, relationships are rewritten by group doctrine, and chess becomes both sanctuary and battleground? In this powerful second part of our convo with Danny Rensch, we return to unpack life after his “purpose ordainment,” and the heartbreak of being separated from his mother by cult coercion. With raw honesty, Danny shares how spiritual manipulation, covert contracts, and collective pressure led to the deepest trauma of his youth and how healing and reconnection became possible, despite loss and pain. We chat about his wild chess tournament sagas, the story of Igor (the inappropriate Russian master with a soft spot for broken kids), and the unraveling of the Church of Immortal Consciousness as generations, money, and ideals collided. Danny gets real about calling things what they are, facing the dark side of “doing good,” and why his redemption arc is proof that you are not what happens to you—you are what you choose to become. We also drop a secret character from his book who collided with NXIVM. File this one under: complex, courageous, and essential listening.Fill in the gaps in our convo and read Danny's gripping memoir, Dark Squares: How Chess Saved My Life. Also, follow him on Instagram, YouTube, Facebook, TikTok, X, and LinkedIn.Also…let it be known that:The views and opinions expressed on A Little Bit Culty do not necessarily reflect the official policy or position of the podcast. Any content provided by our guests, bloggers, sponsors or authors are of their opinion and are not intended to malign any religion, group, club, organization, business, individual, anyone or anything. Nobody's mad at you, just don't be a culty fuckwad.**PRE-ORDER Sarah and Nippy's newest book hereCheck out our amazing sponsorsJoin A Little Bit Culty on PatreonGet poppin' fresh ALBC SwagSupport the pod and smash this linkCheck out our cult awareness and recovery resourcesWatch Sarah's TED Talk and buy her memoir, ScarredCREDITS: Executive Producers: Sarah Edmondson & Anthony AmesProduction Partner: Citizens of SoundCo-Creator: Jess TardyAudio production: Will RetherfordProduction Coordinator: Lesli DinsmoreWriter: Sandra NomotoSocial media team: Eric Skwarzynski and Brooke KeaneTheme Song: “Cultivated” by Jon Bryant co-written with Nygel AsselinSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode is sponsored by Betterhelp.How do you go from barefoot kid to international chess master and co-founder of Chess.com? In this epic first installment, we sat with Danny Rensch to peel back the curtain on his wild journey growing up in the Church of Immortal Consciousness—a high-control Arizona collective commune led by a self-proclaimed trance medium guided by the spirit of "Dr. Duran." Danny shares what life was like growing up in a merged-finances, communal-living environment fueled by spiritual teachings, EST-style group processing, and just enough bathwater-sharing to make any outsider's eyebrows shoot up. From childhood freedom and chaos to early red flags, shifting loyalties, and the beginnings of his path out via chess, Danny's story is a rollercoaster of agency, paradox, and hope. Expect deep dives into cult philosophy, spiritual skepticism, the lure of community, and how genius can bloom in the strangest soil—all before we even get to the chess part. Come for the cult tale and stay for the cliffhanger: part two is a pawn move away.Whether or not you play chess you MUST check out Danny's memoir, Dark Squares: How Chess Saved My Life. Also, follow him on Instagram, YouTube, Facebook, TikTok, X, and LinkedIn.Also…let it be known that:The views and opinions expressed on A Little Bit Culty do not necessarily reflect the official policy or position of the podcast. Any content provided by our guests, bloggers, sponsors or authors are of their opinion and are not intended to malign any religion, group, club, organization, business, individual, anyone or anything. Nobody's mad at you, just don't be a culty fuckwad.**PRE-ORDER Sarah and Nippy's newest book hereCheck out our amazing sponsorsJoin A Little Bit Culty on PatreonGet poppin' fresh ALBC SwagSupport the pod and smash this linkCheck out our cult awareness and recovery resourcesWatch Sarah's TED Talk and buy her memoir, ScarredCREDITS: Executive Producers: Sarah Edmondson & Anthony AmesProduction Partner: Citizens of SoundCo-Creator: Jess TardyAudio production: Will RetherfordProduction Coordinator: Lesli DinsmoreWriter: Sandra NomotoSocial media team: Eric Skwarzynski and Brooke KeaneTheme Song: “Cultivated” by Jon Bryant co-written with Nygel AsselinSUPPORT OUR SPONSORS:This month, don't wait to reach out. Whether you're checking in on a friend, or reaching out to a therapist yourself, Betterhelp makes it easier to take that first step. Our listeners get 10% off their first month at BetterHelp.com/culty.Knock out all your holiday gifting needs today with MeUndies. To get exclusive holiday deals up to 50% off, go to MeUndies.com/culty and enter promo code culty.Take advantage of this exclusive offer: For a limited time get 40% off your first box PLUS a free item in every box for life. Go to Hungryroot.com/culty and use code culty.Don't let financial opportunity slip through the cracks. Use code CULTY at monarch.com in your browser for half off your first year.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Devil's Checkmate On December 16, 2000, 31-year-old Mike Williams vanished while duck hunting on Florida's Lake Seminole. His truck was found. His boat was found. But Mike… was gone. For years, authorities believed he'd drowned—dragged beneath the surface by alligators. But there was no body. No blood. No real evidence of a struggle. What emerged instead was a story of greed, betrayal, and a staged disappearance that unraveled into one of Florida's strangest and most calculated murders. Criminal Mischief digs into how an insurance plot became a cold-blooded crime—and how, 17 years later, the truth finally surfaced from the swamp.

The PEACEMAKER season 2 finale introduced several pieces of DCU lore, including Checkmate, and the prison planet Salvation from the SALVATION RUN limited series. DJ and Roxy discuss what these new developments could mean for the future of James Gunn's DCU, how Nicholas Hoult's Lex Luthor is involved, and what it means for David Corenswet's Superman!Support the International Rescue Committee! https://www.rescue.org/crisis-in-gazaSupport DJ's new Kickstarter! https://www.kickstarter.com/projects/djtalkstrash/graveyardshift?ref=6gd2hoMore DJ!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/djtalkstrash⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠More Roxy! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/roxystriar⁠⁠⁠⁠Theme Music by: Steven James SchmidtFor exclusive bonus podcasts like What We're Into, Mutant Academy, and more, check out our Patreon! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/OnlyStupidAnswers